-+ 0.00%
-+ 0.00%
-+ 0.00%
Changes in Hong Kong stocks | Yiteng Jiahe (06998) rose nearly 2% GB268's clinical trial application for NSCLC and BTC-related new drugs approved by the China Drug Administration
Share
Listen to the news

The Zhitong Finance App learned that Yiteng Jiahe (06998) rose nearly 2%. As of press release, it had risen 1.91% to HK$1.6, with a turnover of HK$256,500.

According to the news, Yitengjiahe announced that the company's highly differentiated and innovative PD-1/CTLA-4/VEGF three-specific antibody GB268 is a single drug or phase II clinical trial application (IND) for treating metastatic (stage IV) non-small cell lung cancer (NSCLC), as well as first-line combination chemotherapy to treat locally advanced or metastatic biliary tract cancer (BTC) that cannot be cured surgically resected, was approved by the China National Drug Administration (China Drug Administration) on November 12, 2026. These two developments indicate that GB268's clinical development plan has been initially approved by the regulatory authorities, and also mark the further deepening of GB268's multi-tumor layout.

GB268 was approved for the first human clinical trial by the State Drug Administration in July 2025. Preliminary data from the single-drug phase I clinical study showed that GB268 was well tolerated in patients with advanced solid tumors in the full dose range, and a wide range of initial efficacy signals were observed in multiple tumors. The relevant clinical data were presented at the European Society of Medical Oncology (ESMO) Annual Meeting in October 2026. In October 2026, GB268 was approved by the State Drug Administration to conduct a phase II clinical trial for first-line treatment of advanced colorectal cancer with combination chemotherapy. GB268 is expected to conduct phase II clinical studies in various solid tumors in the form of a single drug or combination therapy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending